Denosumab has shown to be noninferior to zoledronic acid for the prevention of skeletal-related events and provides an alternative .
Fewer adverse events related to renal toxicity have been noted with denosumab compared with zoledronic acid and may be preferred in this setting .
Purpose To up date guideline recommendations on the role of bone-modifying agents in multiple myeloma .
Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study
Background Cases of impaired renal function have been reported in patients who had been treated with both zoledronic acid and thalidomide for myeloma . Hence , we conducted a safety study of zoledronic acid and thalidomide in myeloma patients participating in a trial of maintenance therapy . Methods Twenty-four patients who were enrolled in a large r and omized trial of thalidomide vs no thalidomide maintenance therapy for myeloma , in which all patients also received zoledronic acid  , were recruited to a pharmacokinetic and renal safety sub- study , and followed for up to 16 months . Results No significant differences by Wilcoxon rank-sum statistic were found in zoledronic acid pharmacokinetics or renal safety for up to 16 months in patients r and omized to thalidomide or not . Conclusion In myeloma patients receiving maintenance therapy , the combination of zoledronic acid and thalidomide appears to confer no additional renal safety risks over zoledronic acid alone
Denosumab has shown to be noninferior to zoledronic acid for the prevention of skeletal-related events and provides an alternative .
Fewer adverse events related to renal toxicity have been noted with denosumab compared with zoledronic acid and may be preferred in this setting .
Purpose To up date guideline recommendations on the role of bone-modifying agents in multiple myeloma .